Hepatitis B Treatment Market by Drug Class (Chemo Therapy, Immunosuppressant Therapy, Nucleoside Analogue), by Route of Administration (Oral, Parenteral, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

 

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

The global Hepatitis B Treatment Market size was estimated at USD 548.84 million in 2021, growing at a CAGR of 10.3% during the forecast period 2021-2027. Hepatitis-B is also known serum hepatitis which is an infectious disease of the liver caused by Hepatitis-B virus (HBV). Hepatitis B is classified into two types namely, acute and chronic. In this condition, the virus interferes with the hepatocytes and the liver became inflamed. Hepatitis-B is commonly caused through parenteral contacts such as blood, body fluids, and sexual intercourse. Hepatitis-B virus is unable to cross the skin or mucous membrane. People with Lymph proliferative disease, Acquired Immuno Deficiency Syndrome (AIDS), and people treated with immunosuppressant drugs and haemodialysis patients are easily develop an infection with Hepatitis-B Virus. The symptoms of the Hepatitis B do not develop until after a few weeks of exposure. The severity in Hepatitis may cause the cirrhosis, liver failure, and hepatocellular carcinoma (HCC). A vaccine is commonly administered to protect people from the infection. Hepatitis B can be prevented by administering the hepatitis B vaccine to newborn babies, avoiding promiscuity and not having multiple sexual partners, and avoiding sharing of injections and razors can also prevent the Hepatitis B infection. Geographically, hepatitis B treatment market is in growing stage, as various government organizations are initiating awareness programs to prevent the hepatitis B infection. Increase in the prevalence of hepatitis B infection and liver cirrhosis might fuel the hepatitis B treatment market. According to the World Health Organization, there are currently 240 million chronic carriers of hepatitis B virus in which approximately 15–25% of carriers will develop cirrhosis, hepatocellular carcinoma (HCC), or liver decompensation, and 780,000 will die each year as a result of their infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their share in global hepatitis b treatment market. For instance, in September 2013, Roche and Inovio Pharmaceuticals collaborated on research, development, and commercialization of Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting hepatitis B and prostate cancer. Similarly, in July 2015, Benitec Biopharma and Biomics Biotechnologies are announced that Benitec has acquired the full rights to the pre-clinical ddRNAi-based hepatitis B (HBV) therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies. In addition, in October 2010, U.S. Food and Drug Administration approved the Baraclude (Entecavir) for hepatitis B treatment with the decompensated liver disease in adults manufactured by Bristol Myers Squibb. Moreover, various drugs for the hepatitis B treatment in the pipeline also expected to propel the hepatitis B treatment market over the forecast period.

Key Developments: In January 2017, Gilead Sciences, Inc announced that the European Commission granted marketing authorization for Vemlidy (tenofovir alafenamide, TAF) for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg) In December 2016, Cipla received an approval from American health regulator to market Entecavir tablets used in the treatment of HBV infection

Global Hepatitis B Treatment Market Summary

Study Period

2023-29

Base Year

2022

CAGR

10.3%

Largest Market

North America

Fastest Growing Market

Europe
Hepatitis B Treatment Market Dynamics

The global Hepatitis B treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis B infection. According to the World Health Organization (WHO), chronic hepatitis B virus infection occurs in majority of the infants. Rising awareness regarding hepatitis B treatment, increase in the healthcare expenditure, rise in the funding in research and development activities for hepatitis B treatment, and various pipeline products for Hepatitis B treatment might fuel the global hepatitis B treatment market over the forecast period. However, high cost of the hepatitis B treatment and medications, less effectiveness of antiviral drugs against hepatitis B infection might hamper the growth of global hepatitis B treatment market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Hepatitis B Treatment Market Segmentation

drug class
  • Chemo Therapy
  • Immunosuppressant
  • Nucleoside Analogue
Route-administration
  • Oral
  • Parenteral
  • Others
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • F. Hoffmann- La Roche Ltd. (Switzerland)
  • GlaxoSmithKline, plc. (U.K.)
  • Bristol-Myers Squibb (U.S)
  • Novartis AG (Switzerland)
  • Merck and Co Inc., (U.S)
  • Novira Therapeutics Inc. (U.S.)
  • Johnson & Johnson Services Inc., (U.S.)
  • Inovio Pharmaceuticals Inc. (U.S.)
  • Benitec biopharma Ltd. (Australia)
  • Gilead Sciences (U.S.)
  • Cipla Inc. (India)
  • Biomics biotechnologies (China)